Pharmaceutical Firm

With its planned product pipeline for complex generic medicines in the next two years, she said in the years to come the company hopes to have up to 40 per cent of its revenue coming from such medicines in the US market.

Sanofi, Boehringer Ingelheim close business swap in India

The closing of swap deal was for the exchange of Sanofi's animal health business and Boehringer Ingelheim's consumer healthcare (CHC) business in the country, a release said here.

Eris Lifesciences files IPO papers with Sebi

"The company expects that listing of the equity Shares will enhance our visibility and brand image and provide liquidity to our shareholders. Listing will also provide a public market for the equity shares in India," Eris said in the draft documents.

Laurus Labs' IPO fully subscribed on final day

The IPO received bids for 2,26,84,270 shares as against total issue size of 2,19,11,308 scrips, garnering a subscription of 1.04 times as per NSE data till 1300 hours.

Laurus Labs' IPO subscribed 61% on second day

The IPO received bids for 1,33,29,155 shares as against total issue size of 2,19,11,308 scrips, as per NSE data till 1700 hours.

Laurus Labs garners Rs 395 crore from anchor investors

The anchor investors are Goldman Sachs India, Nomura Trust and Banking, SBI Mutual Fund, DSP BlackRock and ICICI Prudential Mutual Fund.

Granules India's net profit up 26% to Rs 41 cr in Q2

The company's revenue increased by 3 percent at Rs 364 crore as compared to Rs 353 crore in the corresponding period, a company statement said here.

Strides Shasun to hive off API division as subsidiary

The company's board at its meeting held today has given an in-principle approval to hive-off the API business into a wholly-owned subsidiary, subject to finalising modalities of the transfer, Strides Shasun said in a BSE filing.

Venus Remedies bags Indian patent for antibiotic Vancoplus

Pharmaceutical firm Venus Remedies Ltd, today said it has received Indian product patent for its antibiotic research product Vancoplus. The Indian Patent Office (IPO) granted the licence which is valid till 2025, said Venus.

Merck Q1 net profit up 12.9% to Rs 14 crore

Pharmaceutical firm Merck's first quarter (January-March) net profit grew by 12.9 percent year-on-year to Rs 14 crore.

Aim to see turnover of USD 5 bn by 2020: Cipla Chairman

Cipla reported a better-than-expected second quarter earnings. In an interview to CNBC-TV18, Chairman of the company YK Hamied said that the pharma major is expecting to achieve a turnover of USD 5 billion by the year 2020.